COMMITMENT...MATTERS

NEWS & BUZZ ABOUT HENGRUI

​11/18/2020
​

Hengrui Announced First Patient Dosed with Pyrotinib in PYRAMID-I Phase 3 Pivotal Trial in the United States on November 18th, 2020

​7/24/2020

Hengrui signed agreement with Thermo Fisher Scientific on Companion Diagnostic to identify NSCLC patients for Pyrotinib treatment

​11/19/2019
​

Hengrui announced the initiation of a phase 3 pivotal clinical trial to evaluate the safety and efficacy of pyrotinib on HER2 exon 20 mutated NSCLC patients in the second-line settings.

4/19/2019

Hengrui Therapeutics initiated a global Phase 3 study to investigate the efficacy and safety of camrelizumab and rivoceranib (apatinib) in first line HCC patients.

6/1/2018         

Hengrui Medicine places in Forbes's list of top 100 world's most innovative companies

5/17/2018

Hengrui Medicine featured by Financial Times under "China Pharma Boosts Generics Exports to US"

​4/17/2018
​

Hengrui Medicine featured in Bloomberg Opinion tilted "4,000,000 Reasons to Back China Biotech."

​1/8/2018

TG Therapeutics and Hengrui Medicine announce global license agreement for development and commercialization of novel BTK inhibitor program for the treatment of hematologic malignancies

1/5/2018

Hengrui Medicine and Arcutis partner to development novel immune-mediated dermatology therapy using SHR0302, a potentially best-in-class JAK inhibitor

6/27/2016

Hengrui Medicine and an undisclosed US investment firm invest $100 million on Hengrui Therapeutics Inc to advance clinical trials in Hengrui Therapeutics' pharmaceutical research and development 

5/3/2016

Hengrui Medicine signs a 3-year pact with the MD Anderson Cancer Center at the University of Texas, Houston with an immuno-oncology focus on combination therapies, personalized medicine and new treatment opportunities 

4/25/2016

Hengrui Medicine collaborates with Albert Einstein College of Medicine to advance cancer research and drug discovery

9/3/2015
​

Hengrui Medicine became the first Chinese firm to license a drug candidate to a U.S. biotech: Incyte agreed to pay $795 million in total potential up and milestone payments for ex-China rights to camrelizumab, a PD-1 antibody in phase II clinical trials in China ​

7/30/2015

Hengrui Medicine licenses Rolapitant, an NK-1 receptor antagonist, from Tesaro

​7/15/2015

Hengrui Medicine invests ¥850 million (US$137 million) into the building of a biologics manufacturing plant that follows FDA and EMEA standards with expectations of entering markets outside of China ​​​